UB Paderborn / Katalog / Suche / in CDI

1 – 24 von 24

Sortiert nach

Pharmacological disruption of the Notch transcription factor complex

Proceedings of the National Academy of Sciences - PNAS, 2020-07, Vol.117 (28), p.16292-16301

2020

Link zum Volltext

Verfügbarkeit prüfen

Identification of tumorsphere- and tumor-initiating cells in HER2/Neu-induced mammary tumors

Cancer research (Chicago, Ill.), 2007-09, Vol.67 (18), p.8671-8681

2007

Link zum Volltext

Verfügbarkeit prüfen

The Efficacy of CB-103, a First-in-Class Transcriptional Notch Inhibitor, in Preclinical Models of Breast Cancer

Cancers, 2023-08, Vol.15 (15), p.3957

2023

Link zum Volltext

Verfügbarkeit prüfen

CB‐103: A novel CSL‐NICD inhibitor for the treatment of NOTCH‐driven T‐cell acute lymphoblastic leukemia: A case report of complete clinical response in a patient with relapsed and refractory T‐ALL

EJHaem, 2022-08, Vol.3 (3), p.1009-1012

2022

Link zum Volltext

Verfügbarkeit prüfen

Stem cells living with a Notch

Development (Cambridge), 2013-02, Vol.140 (4), p.689-704

2013

Link zum Volltext

Verfügbarkeit prüfen

Generation and characterization of a Notch1 signaling-specific reporter mouse line

Genesis (New York, N.Y. : 2000), 2012-09, Vol.50 (9), p.700-710

2012

Link zum Volltext

Verfügbarkeit prüfen

Very High Throughput Electrical Cell Lysis and Extraction of Intracellular Compounds Using 3D Carbon Electrodes in Lab-on-a-Chip Devices

Micromachines (Basel), 2012-09, Vol.3 (3), p.574-581

2012

Link zum Volltext

Verfügbarkeit prüfen

Abstract 5799: Characterization and profiling of CB-103, a novel small-molecule protein-protein interaction inhibitor targeting the NOTCH transcription complex

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.5799-5799

2018

Link zum Volltext

Verfügbarkeit prüfen

Abstract 2695: Direct targeting of NOTCH transcription complex by a novel small molecule CB-103 circumvents dose-limiting toxicities associated with pan-NOTCH inhibitors

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.2695-2695

2019

Link zum Volltext

Verfügbarkeit prüfen

In vitro anti‐lymphoma activity of the first‐in‐class pan‐NOTCH transcription inhibitor CB‐103

British journal of haematology, 2023-03, Vol.200 (5), p.669-672

2023

Link zum Volltext

Verfügbarkeit prüfen

Gene expression patterns in adenoid cystic carcinoma with and without diffuse NOTCH1 intracellular domain (NICD1) immunohistochemistry staining

Oral oncology, 2023-11, Vol.146, p.106542-106542, Article 106542

2023

Link zum Volltext

Verfügbarkeit prüfen

Targeting Notch Inhibitors to the Myeloma Bone Marrow Niche Decreases Tumor Growth and Bone Destruction without Gut Toxicity

Cancer research (Chicago, Ill.), 2021-10, Vol.81 (19), p.5102-5114

2021

Link zum Volltext

Verfügbarkeit prüfen

Alzheimer's disease mutations in APP but not γ-secretase modulators affect epsilon-cleavage-dependent AICD production

Nature communications, 2013, Vol.4 (1), p.2246-2246, Article 2246

2013

Link zum Volltext

Verfügbarkeit prüfen

Abstract 408: Development of a first-in-class notch transcription factor inhibitor CB-103 to overcome resistance to chemotherapy and targeted therapies

Cancer research (Chicago, Ill.), 2022-06, Vol.82 (12_Supplement), p.408-408

2022

Link zum Volltext

Verfügbarkeit prüfen

Abstract 1163: Non clinical pharmacology, pharmacokinetics and safety profiling of CB-103: A novel first-in-class small molecule inhibitor of the NOTCH pathway

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.1163-1163

2017

Link zum Volltext

Verfügbarkeit prüfen

Phase 1 study of CB-103, a novel first-in-class inhibitor of the CSL-NICD gene transcription factor complex in human cancers

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.3020-3020

2021

Link zum Volltext

Verfügbarkeit prüfen

Abstract 338: A novel small molecule inhibitor of the Notch transcription activation complex

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.338-338

2016

Link zum Volltext

Verfügbarkeit prüfen

Abstract IA10: Notch signaling and cancer

Molecular cancer research, 2016-04, Vol.14 (4_Supplement), p.IA10-IA10

2016

Link zum Volltext

Verfügbarkeit prüfen

Abstract B061: Targeting lymphomas with the novel first-in-class pan-NOTCH transcription inhibitor CB-103

Molecular cancer therapeutics, 2018-01, Vol.17 (1_Supplement), p.B061-B061

2018

Link zum Volltext

Verfügbarkeit prüfen

First-in-human phase 1-2A study of CB-103, an oral Protein-Protein Interaction Inhibitor targeting pan-NOTCH signalling in advanced solid tumors and blood malignancies

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.TPS2619-TPS2619

2018

Link zum Volltext

Verfügbarkeit prüfen

Identification of tumorsphere-and tumor-initiating cells in HER2/Neu-lnduced mammary tumors

Cancer research (Chicago, Ill.), 2007, Vol.67 (18), p.8671-8681

2007

Link zum Volltext

Verfügbarkeit prüfen

Alzheimer's disease mutations in APP but not [gamma]-secretase modulators affect epsilon-cleavage-dependent AICD production

Nature communications, 2013-08, Vol.4, p.2246

2013

Link zum Volltext

Verfügbarkeit prüfen

Evidence that Pten loss induces mammary tumours by targeting stem/progenitor cells

Lehal, Rajwinder Singh

2007

Link zum Volltext
ProQuest

CB-103: A novel CSL-NICD inhibitor for the treatment of NOTCH-driven T-cell acute lymphoblastic leukemia: A case report of complete clinical response in a patient with relapsed and refractory T-ALL

EJHaem, 2022, Vol.3 (3), p.1009-1012

2022

Link zum Volltext

Verfügbarkeit prüfen

1 – 24 von 24

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(22)
Mit Volltextzugriff
(23)

Publikationsform

Sprache

Englisch
(24)
Japanisch
(3)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Pharmacological disruption of the Notch transcription factor complex

Identification of tumorsphere- and tumor-initiating cells in HER2/Neu-induced mammary tumors

The Efficacy of CB-103, a First-in-Class Transcriptional Notch Inhibitor, in Preclinical Models of Breast Cancer

CB‐103: A novel CSL‐NICD inhibitor for the treatment of NOTCH‐driven T‐cell acute lymphoblastic leukemia: A case report of complete clinical response in a patient with relapsed and refractory T‐ALL

Stem cells living with a Notch

Generation and characterization of a Notch1 signaling-specific reporter mouse line

Very High Throughput Electrical Cell Lysis and Extraction of Intracellular Compounds Using 3D Carbon Electrodes in Lab-on-a-Chip Devices

Abstract 5799: Characterization and profiling of CB-103, a novel small-molecule protein-protein interaction inhibitor targeting the NOTCH transcription complex

Abstract 2695: Direct targeting of NOTCH transcription complex by a novel small molecule CB-103 circumvents dose-limiting toxicities associated with pan-NOTCH inhibitors

In vitro anti‐lymphoma activity of the first‐in‐class pan‐NOTCH transcription inhibitor CB‐103

Gene expression patterns in adenoid cystic carcinoma with and without diffuse NOTCH1 intracellular domain (NICD1) immunohistochemistry staining

Targeting Notch Inhibitors to the Myeloma Bone Marrow Niche Decreases Tumor Growth and Bone Destruction without Gut Toxicity

Alzheimer's disease mutations in APP but not γ-secretase modulators affect epsilon-cleavage-dependent AICD production

Abstract 408: Development of a first-in-class notch transcription factor inhibitor CB-103 to overcome resistance to chemotherapy and targeted therapies

Abstract 1163: Non clinical pharmacology, pharmacokinetics and safety profiling of CB-103: A novel first-in-class small molecule inhibitor of the NOTCH pathway

Phase 1 study of CB-103, a novel first-in-class inhibitor of the CSL-NICD gene transcription factor complex in human cancers

Abstract 338: A novel small molecule inhibitor of the Notch transcription activation complex

Abstract IA10: Notch signaling and cancer

Abstract B061: Targeting lymphomas with the novel first-in-class pan-NOTCH transcription inhibitor CB-103

First-in-human phase 1-2A study of CB-103, an oral Protein-Protein Interaction Inhibitor targeting pan-NOTCH signalling in advanced solid tumors and blood malignancies

Identification of tumorsphere-and tumor-initiating cells in HER2/Neu-lnduced mammary tumors

Alzheimer's disease mutations in APP but not [gamma]-secretase modulators affect epsilon-cleavage-dependent AICD production

Evidence that Pten loss induces mammary tumours by targeting stem/progenitor cells

CB-103: A novel CSL-NICD inhibitor for the treatment of NOTCH-driven T-cell acute lymphoblastic leukemia: A case report of complete clinical response in a patient with relapsed and refractory T-ALL

Suchergebnisse filtern